Novartis AG (SWX:NOVN)
94.03
+1.30 (1.40%)
May 30, 2025, 5:31 PM CET
Novartis AG Revenue
Novartis AG had revenue of $13.62B USD in the quarter ending March 31, 2025, with 12.38% growth. This brings the company's revenue in the last twelve months to $53.22B, up 11.50% year-over-year. In the year 2024, Novartis AG had annual revenue of $51.72B with 10.85% growth.
Revenue (ttm)
$53.22B
Revenue Growth
+11.50%
P/S Ratio
3.92
Revenue / Employee
$701.37K
Employees
75,883
Market Cap
184.23B CHF
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 51.72B | 5.06B | 10.85% |
Dec 31, 2023 | 46.66B | 3.20B | 7.36% |
Dec 31, 2022 | 43.46B | -513.00M | -1.17% |
Dec 31, 2021 | 43.97B | -5.92B | -11.87% |
Dec 31, 2020 | 49.90B | 1.22B | 2.51% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Roche Holding AG | 62.40B |
Lonza Group AG | 6.57B |
Alcon | 8.77B |
Galderma Group AG | 4.02B |
Sandoz Group AG | 9.41B |
Straumann Holding AG | 2.50B |
Sonova Holding AG | 3.87B |
Ypsomed Holding AG | 748.87M |
Novartis AG News
- 1 day ago - Alcon Secures First FDA Approval Since Novartis Spin-Off In 2019 - Benzinga
- 3 days ago - Novartis announces commencement of tender offer to acquire Regulus Therapeutics - GlobeNewsWire
- 10 days ago - If I Could Only Buy 2 Dividend Stocks Right Now (May 2025 Edition) - Seeking Alpha
- 15 days ago - New Novartis data at ASCO and EHA showcase momentum of pioneering portfolio with promising pipeline - GlobeNewsWire
- 16 days ago - Incyte and Novartis settle royalties dispute related to Jakafi - Seeking Alpha
- 16 days ago - GSK To Buy Phase-3 Ready Liver Disease Drug For Up To $2 Billion - Benzinga
- 16 days ago - Greece needs urgent cardiovascular disease action plan, says leading health executive - EURACTIV.com
- 18 days ago - Trump wants to slash U.S. drug prices with 'most favored nation' policy – here's what to know - CNBC